Abbott downgraded at Argus on guidance cut

What happened

Abbott Laboratories shares traded lower on Tuesday after three straight sessions of gains, as Argus Research cut its 12-month rating to Hold from Buy. Argus cited Abbott's decision to trim its full-year comparable sales growth outlook to about 6%, down from 6.5% to 7.5%.

Confirmed

Global impact / market context

A lower sales growth forecast signals Abbott's key drivers, electrophysiology and diabetes care, are slowing. Because Argus also flags pricing pressure, tariff-related costs, and supply chain issues, investors face weaker revenue growth and higher costs at the same time, which can weigh on profit.

Analyst inference

The downgrade to Hold, while keeping a long-term Buy rating, suggests analysts see near-term trouble rather than a broken business. Abbott's planned spin-off of its Nutrition segment is framed as a path to faster growth and better profit per sale, but the analyst wants proof of improved sales first.

Analyst inference

What to watch

1. Abbott set its full-year outlook for comparable sales growth at about 6%, down from 6.5% to 7.5% previously, so future updates on whether sales growth stabilizes near that level matter. Confirmed
2. Argus said it will upgrade Abbott to Buy once signs of improved top-line growth emerge, which means investors can watch whether sales growth, a company's total revenue growth, actually reaccelerates. Proposed
3. Watch the planned separation of Abbott's Nutrition segment, since the analyst argues it could create a faster-growing, higher-margin company, but execution and regulatory issues in pediatric nutrition remain risks. Analyst inference

Evidence

• seekingalpha.com